Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaTSCAN Diagnostic Efficacy in Chinese Patients with Parkinsonian Syndromes
NCT04193527Phase 3Completed
- Sponsor
- GE HealthCare
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ioflupane I-123 in parkinsonian disorders, sponsored by GE HealthCare. Primary endpoints: Sensitivity of Blinded Independent Read at Day 1 and Specificity of Blinded Independent Read at Day 1. Started Jun 2020; status: completed.
02
Drugs
ioflupane I-123
03
Conditions
parkinsonian disorders
Beyond the preview
Go deeper on NCT04193527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193527.